The Myeloma Drug Tracker shows where drugs are in the clinical trial pathway as potential treatments for myeloma. Available drugs are ones which have already been licensed for use in myeloma.
Using the filters below, you can explore the drug types and trial stages. Clicking on a drug will provide additional information and you can download an Infosheet if there is one available.
Further information can be found on our website under Clinical Trials and Novel Drugs.
Filter by drug type
30 Immunotherapy
9 Epigenetic Drug
6 Proteasome Inhibitor
26 Cell Signalling/Cycle
Filter by trial stage
Order by
Drug name
Drugs in Phase I
I
Drugs in Phase II
II
Drugs in Phase III
III
Available Drugs
A
Immunotherapy | Drugs in Phase I
CD19+ CAR-T cell therapy is a new treatment being investigated in myeloma. It belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and genetically engineered to recognise myeloma cells more easily. CD19+ CAR-T cells are designed to recognise CD19, a protein found on the surface of immature myeloma cells. Once attached, they remove and destroy the immature myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
Nelfinavir is an antiretroviral drug normally used in the treatment of human immunodeficiency virus (HIV). It is also being tested in myeloma and works by interacting with proteasomes as well as by blocking the PI3 kinase/Akt cell signalling pathway. Nefinavir is thought to work by enhancing the activity of drugs such as bortezomib and lenalidomide.
Immunotherapy | Drugs in Phase II
Ipilimumab is a new drug being tested in myeloma and other cancers. It belongs to a class of drug known as checkpoint inhibitors and targets a protein called CTLA-4 which normally dampens the immune response. Ipilimumab therefore increases the activity of the immune system to recognise and destroy myeloma cells.
Immunotherapy | Drugs in Phase I
BB2121 is a new treatment being investigated in myeloma. It belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and genetically engineered to recognise myeloma cells more easily. BB2121 is designed to recognise B cell maturation antigen (BCMA), a protein found on the surface of myeloma cells. Once attached, BB2121 removes and destroys the myeloma cells.
Epigenetic Drug | Drugs in Phase I
AR-42 is a new drug being tested in myeloma and other cancers. It belongs to a class of drug known as histone deacetylase inhibitors.
Cell Signalling/Cycle | Drugs in Phase I
Napabucasin (previously known as BBI608) is a new drug being tested in myeloma. It belongs to a class of drug known as a cancer stem cell pathway inhibitor and specifically targets the STAT3 signalling pathway. In doing so, it prevents the growth and proliferation of myeloma cells.
Immunotherapy | Drugs in Phase I
Atezolizumab (previously known as MPDL3280A) is a new drug being tested in myeloma. It belongs to a class of drug known as checkpoint inhibitors and targets a protein called PDL-1 which is normally involved in dampening the immune response. Atezolizumab therefore increases the activity of the immune system to recognise and destroy myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
Buparlisib is a new oral drug being investigated as a treatment for myeloma. It belongs to a class of drug known as a phosphatidlyinositol 3-kinase (PI3 kinase) inhibitor and works by disrupting the cell signals that control the growth and survival of myeloma cells, causing them to die.
Other | Drugs in Phase I
Roneparstat, previously known as SST0001, is a new drug being tested in myeloma. It belongs to a class of drug known as the heparanase inhibitors and works by disrupting the tumour microenvironment and inhibiting the growth and survival of myeloma cells.
Immunotherapy | Drugs in Phase I
ABBV-838 is a new drug being investigated as a treatment for myeloma. It consists of a chemotherapy drug attached to a monoclonal antibody which helps to deliver the drug to myeloma cells. This type of drug is called an antibody-drug conjugate.
Chemotherapy | Available Drugs
Fludarabibe is a chenotherapy drug used as a treatment for myeloma and other cancers.
Immunotherapy | Drugs in Phase I
AMG-224 is a new drug being tested in myeloma. It consists of a chemotherapy drug attached to a monoclonal antibody which helps to deliver the drug to myeloma cells. This type of drug is called an antibody-drug conjugate.
Cell Signalling/Cycle | Drugs in Phase II
TAS-120 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs which works by blocking the FGF receptor and its downstream signalling mechanism, with the aim of preventing the growth and survival of myeloma cells.
Other | Drugs in Phase I
DS-3032b is a new drug being investigated in myeloma. It is the first in a completely new class of drug known as an MDM2 (murine double minute 2) inhibitor which works by restoring the cell death mechanism in myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
ACP-319 is a new drug being tested as a treatment for myeloma. It belongs to a class of drug known as protein kinase inhibitors and specifically blocks the PI3 kinase cell signalling pathway. The result is that it prevents the growth and survival of myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
ACP 196 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drug known as a Bruton tyrosine kinase inhibitor.
Cell Signalling/Cycle | Drugs in Phase II
DTP3 is a new drug being tested in myeloma. It belongs to a class of drugs which works by inhibiting the NF KB signalling pathway, thus preventing the growth and survival of myeloma cells.
Epigenetic Drug | Drugs in Phase I
BAY1238097 is a new drug being tested in myeloma and other cancers. It belongs to a class of drugs known as BET inhibitors.
Cell Signalling/Cycle | Drugs in Phase II
GSK2141795 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as Akt inhibitors
Immunotherapy | Drugs in Phase I
GSK-2857916 is a new drug being investigated as a treatment for myeloma. It consists of a chemotherapy drug attached to an antibody which helps deliver the drug to myeloma cells. This type of drug is called an antibody-drug conjugate.
Immunotherapy | Drugs in Phase I
Urelumab, previously known as BMS-663513 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and by targeting the CD137 protein, stimulates the immune system to destroy and remove myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
RO5126766 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called protein kinase inhibitors and works by targeting two proteins, RAF and MEK, at the same time.
Other | Drugs in Phase I
Reolysin is a new treatment being investigated in myeloma and other cancers. It is as an oncolytic virus, a type of virus that preferentially infects and kills cancer cells.
Cell Signalling/Cycle | Drugs in Phase I
Palbociclib is a drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called cyclin-dependent kinases and works by disrupting the cell cycle, causing cell death.
Immunotherapy | Drugs in Phase I
Lirilumab, previously known as IPH-2102, is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and works by activating the immune system to destroy and remove myeloma cells.
Immunotherapy | Available Drugs
Thalidomide is a drug that is used as treatment for myeloma. It belongs to a class of drugs called immunomodulatory drugs (IMiDs).
Immunotherapy | Drugs in Phase III
Pembrolizumab is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as checkpoint inhibitors and targets the protein PD-1 which normally dampens the immune response. Pembrolizumab therefore increases the activity of the immune system to recognise and destroy myeloma cells.
Other | Drugs in Phase I
I-131 CLR1404 is a new drug being investigated as a treatment for myeloma. It is a type of drug known as a small molecule radiopharmaceutical and is designed to deliver a dose of radiation specifically to cancer cells.
Cell Signalling/Cycle | Drugs in Phase I
Dinaciclib is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as cyclin-dependent kinase inhibitors which works by disrupting the cell cycle and causing cell death.
Cell Signalling/Cycle | Drugs in Phase I
CUDC-907 is a new drug being investigated as a treatment for myeloma. It is unique in that it has a dual mechanism of action, acting both as a histone deacetylase inhibitor and a protein kinase inhibitor.
Epigenetic Drug | Drugs in Phase I
CBI-0610 is a new drug being investigated as a treatment for myeloma. It belongs to a novel class of drugs called BET protein bromodomain inhibitors and works by interfering with the structure of DNA, leading to cell death.
Other | Drugs in Phase I
CB-839 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called glutaminase inhibitors and works by disrupting the cell’s metabolic pathway, leading to cell death.
Other | Drugs in Phase I
CB-5083 is a new drug being investigated as a treatment for myeloma. It belongs to a novel class of drugs known as p97 inhibitors, and works by disrupting the balance of protein synthesis and break down leading to cell death.
Proteasome Inhibitor | Drugs in Phase I
Marizomib, previously known as NPI-0052 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as proteasome inhibitors and is given intravenously (into the vein).
Epigenetic Drug | Drugs in Phase II
Romidepsin is a drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase inhibitors.
Immunotherapy | Drugs in Phase II
Indatuximab ravtansine, previously known as BT-062, is a new drug being investigated as a treatment for myeloma. It consists of a chemotherapy drug attached to an antibody which helps deliver the drug to myeloma cells. This type of drug is called an antibody-drug conjugate.
Immunotherapy | Drugs in Phase II
ImMucin is a cancer vaccine being investigated as a treatment for myeloma. It is intended to stimulate the patient’s own immune system to recognise the MUC-1 protein on the surface of myeloma cells and destroy them.
Immunotherapy | Drugs in Phase II
CART-138 is a new treatment being investigated in myeloma. It belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy and involves T-cells being taken from the patient and genetically engineered to recognise myeloma cells more easily. CART-138 is designed to recognise CD-138 a protein found on the surface of myeloma cells. Once attached, CART-138 removes and destroys the myeloma cells.
Immunotherapy | Drugs in Phase II
ALT-803 is a new dug being investigated as a treatment for myeloma. It belongs to a class of drugs called cytokine superagonists and works by stimulating the immune system to destroy and remove myeloma cells.
Other | Drugs in Phase II
Fenofibrate is a drug being investigated as a treatment for myeloma. It is normally used to reduce cholesterol levels but appears to stop myeloma cells from removing unwanted proteins, leading to cell death.
Cell Signalling/Cycle | Drugs in Phase II
Trametinib is a drug being investigated as a treatment for myeloma. It belomgs to a class of drugs called protein kinase inhibitors and targets the protein MEK.
Cell Signalling/Cycle | Drugs in Phase II
Dabrafenib is a new drug being investigated as a treatment for myeloma and other cancer patients who specifically have the BRAF V600E mutation. It belongs to a class of drugs known as protein kinase inhibitors and specifically targets the B-RAF enzyme.
Cell Signalling/Cycle | Drugs in Phase II
Sonidegib, previously known as LDE-225, is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs that inhibits the hedgehog signalling pathway.
Other | Drugs in Phase II
Selinexor, previously known as KPT-330, is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
Immunotherapy | Drugs in Phase II
Pidilizumab is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs called monoclonal antibodies and by targeting the protein PD-1, stimulates the immune system to attack myeloma cells.
Other | Drugs in Phase II
LCL-161 is a new drug being investigated as a new treatment for myeloma. It belongs to a class of drug known as IAP inhibitors and works by blocking pro-survival mechanisms within the cell.
Epigenetic Drug | Drugs in Phase I
ACY-241 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase inhibitors.
Other | Drugs in Phase III
Venetoclax (previously ABT-199) is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known pro-survival inhibitors, which work by accelerating cancer cell death.
Other | Available Drugs
Prednisolone is a steroid drug which is given alone or in combination with other drugs as a treatment for myeloma.
Other | Available Drugs
Zoledronic acid, also known as Zometa, is used in the treatment and prevention of myeloma bone disease. It belongs to a class of drug known as bisphosphonates.
Other | Available Drugs
Mozobil is a drug used to help mobilise stem cells from the bone marrow into the blood so that they can be harvested in preparation for high-dose therapy and stem cell transplantation.
Immunotherapy | Drugs in Phase II
DKN-01 is a new drug being investigated for the treatment of myeloma bone disease. It belongs to a class of drugs known as monoclonal antibodies and targets the protein called DKK-1.
Immunotherapy | Drugs in Phase II
MOR202 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets the CD38 protein found on the surface of myeloma cells.
Proteasome Inhibitor | Drugs in Phase II
Oprozomib is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as proteasome inhibitors and is taken by mouth.
Other | Drugs in Phase II
Pralatrexate is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as metabolic inhibitors, specifically an anti-folate.
Immunotherapy | Drugs in Phase II
PAT-SM6 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets a protein called GRP78.
Cell Signalling/Cycle | Drugs in Phase I
PRLX 93936 is a new drug being tested as a treatment for myeloma. It is a small molecule anti-cancer treatment that specifically targets the cell signalling protein, RAS.
Immunotherapy | Drugs in Phase II
PVX-410 is a vaccine that is being tested as a treatment for smouldering myeloma.
Epigenetic Drug | Drugs in Phase II
Ricolinostat is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors and selectively inhibits HDAC 6
Other | Drugs in Phase II
SNS01-T is a new drug being tested as a treatment for myeloma and other blood cancers. It represents a new approach to treatment involving the use of nanoparticle technology.
Other | Drugs in Phase II
TH-302 is a new drug being investigated as a treatment for myeloma and other cancers. It is a drug designed to be activated under conditions of low oxygen (hypoxia), a hallmark of many cancers.
Chemotherapy | Drugs in Phase II
Amrubicin is a chemotherapy agent used to treat many different cancers. It is being tested as a treatment for myeloma.
Immunotherapy | Drugs in Phase I
Ulocuplumab, previously known as BMS-936564, is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets a protein called CXCR4.
Other | Drugs in Phase I
CC-122 is a new drug being tested as a treatment for myeloma. It has multiple mechanisms of actions (pleiotropic) including effects on the immune system, blood vessel formation and cell signalling pathways.
Cell Signalling/Cycle | Drugs in Phase I
CC-115 is a new drug being tested as a treatment for myeloma. It belongs to a new class of experimental drugs known as dual DNA protein kinase and mammalian target of rapamycin (mTOR) inhibitors.
Cell Signalling/Cycle | Drugs in Phase II
Cabozantinib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors.
Cell Signalling/Cycle | Drugs in Phase I
Afuresertib, previously known as GSK2110183 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as AKT inhibitors.
Cell Signalling/Cycle | Drugs in Phase II
LGH-447 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as Pim kinase inhibitors.
Immunotherapy | Drugs in Phase III
Nivolumab is a new drug being tested as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as checkpoint inhibitors and targets the protein PD-1 which normally helps to dampen the immune response. Nivolumab therefore increases the activity of the immune system to recognise and destroy myeloma cells.
Immunotherapy | Drugs in Phase II
SAR650984 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets the protein CD38 found on the surface of myeloma cells.
Chemotherapy | Drugs in Phase II
Azacitidine is a chemotherapy drug used in the treatment of blood cell disorders and cancers. It is being tested as a treatment for myeloma.
Immunotherapy | Drugs in Phase I
The WT-1 vaccine is being tested as a treatment for myeloma. It works by activating the immune system to target WT-1, a protein found on the surface of myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
Vemurafenib is a drug being investigated as a treatment for myeloma and other cancer patients who specifically have the BRAF V600E mutation. It belongs to a class of drugs known as protein kinase inhibitors and specifically targets the B-RAF enzyme.
Epigenetic Drug | Drugs in Phase II
CHR 3996 is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Other | Drugs in Phase II
Tosedostat is a new drug being investigated as a treatment for myeloma. It belongs to a class of drugs known as aminopeptidase inhibitors.
Chemotherapy | Available Drugs
Etoposide is a chemotherapy drug used as a treatment for myeloma and other cancers
Chemotherapy | Available Drugs
Cisplatin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Chemotherapy | Available Drugs
Doxorubicin is a chemotherapy drug used as a treatment for myeloma and other cancers.
Other | Drugs in Phase III
Plitidepsin is a novel anti-cancer drug of marine origin that is being investigated for as a treatment for myeloma.
Epigenetic Drug | Drugs in Phase III
Vorinostat is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
Cell Signalling/Cycle | Drugs in Phase II
Sotatercept, previously known as ACE-011, is a new drug being investigated for the treatment of myeloma, myeloma bone disease and anaemia. It is a synthetic protein that targets cell signalling pathways.
Immunotherapy | Drugs in Phase II
BI-505 is a new drug being investigated for the treatment of smouldering myeloma. It belongs to a class of drugs known as monoclonal antibodies and targets the protein I-CAM found on the surface of myeloma cells.
Cell Signalling/Cycle | Drugs in Phase II
Everolimus is a new being investigated for the treatment of myeloma and other cancers. It belongs to a class of drugs known as mammalian target of rapamycin (mTOR) inhibitors
Cell Signalling/Cycle | Drugs in Phase II
Ibrutinib is a new drug being investigated as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as protein kinase inhibitors and specifically inhibits the proyein, Bruton’s tyrosine kinase.
Chemotherapy | Drugs in Phase II
Melflufen is a modified version of the chemotherapy drug melphalan that is being investigated as a treatment for myeloma.
Cell Signalling/Cycle | Drugs in Phase II
Filanesib, previously known as ARRY-520, is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as kinesin spindle inhibitors and inhibits cell division.
Other | Drugs in Phase II
Linsitinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as insulin-like growth factor inhibitors.